Isavuconazonium Sulfate Capsules (Cresemba) are a triazole antifungal agent primarily indicated for the treatment of invasive aspergillosis and mucormycosis.

Precautions for Administration of Isavuconazonium Sulfate Capsules (Cresemba)

Pre-Treatment Assessment

A comprehensive assessment must be conducted before initiating treatment with Isavuconazonium Sulfate Capsules.

First, confirm that the patient has no history of allergy to this medication or other azole antifungal agents (e.g., ketoconazole, fluconazole, itraconazole).

Evaluate whether the patient is concurrently using strong CYP3A4 inhibitors (e.g., ketoconazole, high-dose ritonavir) or inducers (e.g., rifampicin, carbamazepine, St. John's Wort, long-acting barbiturates). These drugs significantly affect the blood concentration of isavuconazole and are contraindicated for combined use.

Also confirm that the patient has no family history of short QT syndrome, as isavuconazole may further shorten the QT interval.

Administration in Special Populations

Patients with hepatic impairment: No dose adjustment is required for patients with mild to moderate hepatic impairment (Child-Pugh Class A and B). However, patients with severe hepatic impairment (Child-Pugh Class C) should only use this medication if the benefit outweighs the risk, and enhanced clinical monitoring is necessary.

Patients with renal impairment: No dose adjustment is required for patients with renal impairment (including end-stage renal disease).

Elderly patients (≥65 years old): No dose adjustment is needed, but some elderly female patients may experience increased drug exposure and require close observation.

Pregnant women: Use during pregnancy may cause harm to the fetus. Patients should be informed of the risks and advised to use effective contraceptive measures. Lactating women should discontinue breastfeeding.

Management of Drug Interactions

Isavuconazonium sulfate has significant interactions with a variety of drugs.

As a sensitive substrate of CYP3A4, its concentration is significantly affected by CYP3A4 inhibitors or inducers.

As a moderate inhibitor of CYP3A4, P-gp, and OCT2, isavuconazole can increase the blood concentrations of drugs such as cyclosporine, sirolimus, tacrolimus, midazolam, and digoxin.

Therapeutic drug monitoring and dose adjustment should be performed when using these drugs concurrently.

Concurrent use with vincristine may increase the risk of neurotoxicity and should be avoided.

Key Administration Technical Points

Isavuconazonium Sulfate Capsules can be taken with or without food, but must be swallowed whole. Do not chew, crush, dissolve, or open the capsules.

For patients unable to take oral medications, switching to the intravenous formulation may be considered. The capsule formulation must not be administered via a nasogastric tube.

Monitoring During Administration of Isavuconazonium Sulfate Capsules (Cresemba)

Hepatic Function Monitoring

Drug-induced liver injury may occur during treatment with isavuconazonium sulfate, manifested by elevated ALT, AST, alkaline phosphatase, total bilirubin, etc.

Baseline liver function tests should be performed before the start of treatment, and regular monitoring should be conducted during treatment.

If clinical symptoms of hepatitis, cholestasis, or liver failure occur (e.g., pruritus, jaundice, flu-like symptoms, nausea, vomiting, extreme fatigue), the medication should be discontinued immediately and appropriate treatment provided.

Patients with a history of severe underlying diseases (e.g., hematologic malignancies) have a higher risk of developing severe hepatotoxicity and require special attention.

Infusion Reaction Monitoring

Infusion-related reactions may occur during intravenous administration, manifested by hypotension, dyspnea, chills, dizziness, paresthesia, etc.

If these reactions occur, the infusion should be stopped immediately. To reduce the risk, the intravenous formulation must be administered through an infusion set with an in-line filter (pore size 0.2-1.2 μm), and the infusion time should be no less than 1 hour.

The intravenous line must be flushed with 0.9% sodium chloride injection or 5% dextrose injection before and after infusion.

Allergic Reaction Monitoring

Isavuconazonium sulfate may cause severe allergic reactions, including anaphylactic shock (which can be fatal) and severe skin reactions (e.g., Stevens-Johnson syndrome).

During medication use, if symptoms such as swelling of the face/lips/tongue, dyspnea, wheezing, severe pruritus, skin redness, dizziness, fainting, sweating, or palpitations occur, the medication should be discontinued immediately and emergency medical assistance sought.

Patients with a history of allergy to other azole drugs should be closely monitored for signs of allergic reactions during use.